Meeting
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
Authors
Jacob J. Adashek
University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Jacob J. Adashek , Shumei Kato , Sarabjot Pabla , Mary Nesline , Jeffrey M. Conroy , Vivek Subbiah , Paul DePietro , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2561)
DOI
10.1200/JCO.2022.40.16_suppl.2561
Abstract #
2561
Poster Bd #
216
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
First Author: Yu Fujiwara
Poster
2022 ASCO Annual Meeting
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
First Author: Hirotaka Miyashita
Poster
2020 ASCO Virtual Scientific Program
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
First Author: Alona Zer
Poster
2020 ASCO Virtual Scientific Program
Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
First Author: Jacob J. Adashek